Leiomyosarcoma

Summary

Leiomyosarcoma (MONDO:0005058) is a disease (an umbrella term covering 31 Mondo subtypes) with 3 cohort genes and 101 clinical trials. Top therapeutic interventions include trabectedin, pazopanib, and dacarbazine.

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Umbrella term: 31 Mondo subtypes
• Cohort genes: 3
• ClinVar variants: 1
• Clinical trials: 101

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	leiomyosarcoma
Mondo ID	MONDO:0005058
EFO	EFO:0000564
MeSH	D007890
Orphanet	64720
DOID	DOID:1967
NCIT	C3158
SNOMED CT	443719001
UMLS	C0023269
MedGen	9711
GARD	0006880
MedDRA	10024189
NORD	1356
Is cancer (heuristic)	no

Also known as: leiomyosarcoma · leiomyosarcoma (excluding uterine leiomyosarcoma) · leiomyosarcoma - not uterine · leiomyosarcoma, malignant · Leiomyosarcomas

Data availability: 1 ClinVar variant · 2 GenCC gene-disease records · 36 cell lines · 15 intOGen driver records.

Disease family

An umbrella term covering 31 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › muscle cancer › smooth muscle cancer › leiomyosarcoma

Subtypes (31): fallopian tube leiomyosarcoma, bone leiomyosarcoma, inflammatory leiomyosarcoma, conventional leiomyosarcoma, central nervous system leiomyosarcoma, colon leiomyosarcoma, heart leiomyosarcoma, ovary leiomyosarcoma, epithelioid leiomyosarcoma, lung leiomyosarcoma, myxoid leiomyosarcoma, small intestine leiomyosarcoma, cutaneous leiomyosarcoma, gallbladder leiomyosarcoma, esophagus leiomyosarcoma, gastric leiomyosarcoma, prostate leiomyosarcoma, vagina leiomyosarcoma, retroperitoneal leiomyosarcoma, breast leiomyosarcoma, vulvar leiomyosarcoma, kidney leiomyosarcoma, laryngeal leiomyosarcoma, mediastinum leiomyosarcoma, liver leiomyosarcoma, rectum leiomyosarcoma, pulmonary vein leiomyosarcoma, pulmonary artery leiomyosarcoma, superior vena cava leiomyosarcoma, leiomyosarcoma of the corpus uteri, leiomyosarcoma of the cervix uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
128042	NM_007194.4(CHEK2):c.1100del (p.Thr367fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 33 · Orphanet: 22 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FH	Moderate	Autosomal dominant	leiomyosarcoma	16
PTEN	Moderate	Autosomal recessive	leiomyosarcoma	17

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FH	Orphanet:24	Fumaric aciduria
FH	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
FH	Orphanet:523	Hereditary leiomyomatosis and renal cell cancer
PTEN	Orphanet:109	Bannayan-Riley-Ruvalcaba syndrome
PTEN	Orphanet:137608	Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
PTEN	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
PTEN	Orphanet:201	Cowden syndrome
PTEN	Orphanet:210548	Macrocephaly-intellectual disability-autism syndrome
PTEN	Orphanet:2969	Proteus-like syndrome
PTEN	Orphanet:494547	Squamous cell carcinoma of the hypopharynx
PTEN	Orphanet:494550	Squamous cell carcinoma of the larynx
PTEN	Orphanet:500464	Squamous cell carcinoma of the nasal cavity and paranasal sinuses
PTEN	Orphanet:500478	Squamous cell carcinoma of the oropharynx
PTEN	Orphanet:502363	Squamous cell carcinoma of the oral cavity
PTEN	Orphanet:502366	Squamous cell carcinoma of the lip
PTEN	Orphanet:65285	Lhermitte-Duclos disease
PTEN	Orphanet:79076	Juvenile polyposis of infancy
CHEK2	Orphanet:1331	Familial prostate cancer
CHEK2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
CHEK2	Orphanet:440437	Familial colorectal cancer Type X
CHEK2	Orphanet:524	Li-Fraumeni syndrome
CHEK2	Orphanet:668	Osteosarcoma

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FH	HGNC:3700	ENSG00000091483	P07954	Fumarate hydratase, mitochondrial	gencc
PTEN	HGNC:9588	ENSG00000171862	P60484	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	gencc
CHEK2	HGNC:16627	ENSG00000183765	O96017	Serine/threonine-protein kinase Chk2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FH	Fumarate hydratase, mitochondrial	Catalyzes the reversible stereospecific interconversion of fumarate to L-malate.
PTEN	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins.
CHEK2	Serine/threonine-protein kinase Chk2	Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Phosphatase	1	28.0×	0.106
Kinase	1	9.2×	0.157
Enzyme (other)	1	4.0×	0.230

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FH	Enzyme (other)	yes	4.2.1.2	Fumarate_lyase_fam, Fum_hydII, L-Aspartase-like
PTEN	Phosphatase	yes	3.1.3.16	Tyr_Pase_dom, Tyr_Pase_cat, Tensin_C2-dom
CHEK2	Kinase	yes	2.7.11.1	FHA_dom, Prot_kinase_dom, Ser/Thr_kinase_AS

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
body of tongue	1
cardiac ventricle	1
heart right ventricle	1
calcaneal tendon	1
endothelial cell	1
sperm	1
lower esophagus mucosa	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FH	292	ubiquitous	marker	heart right ventricle, body of tongue, cardiac ventricle
PTEN	256	ubiquitous	marker	sperm, endothelial cell, calcaneal tendon
CHEK2	183	ubiquitous	marker	primordial germ cell in gonad, lower esophagus mucosa, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PTEN	11,626
CHEK2	4,795
FH	3,709

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CHEK2	O96017	38
PTEN	P60484	12
FH	P07954	7

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 23. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PTEN Loss of Function in Cancer	1	1903.3×	0.012	PTEN
Regulation of PTEN mRNA translation	1	380.7×	0.020	PTEN
Regulation of PTEN localization	1	346.1×	0.020	PTEN
Stabilization of p53	1	253.8×	0.020	CHEK2
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	1	223.9×	0.020	CHEK2
Regulation of TP53 Activity through Methylation	1	181.3×	0.020	CHEK2
Synthesis of IP3 and IP4 in the cytosol	1	141.0×	0.020	PTEN
Citric acid cycle (TCA cycle)	1	141.0×	0.020	FH
Transcriptional Regulation by MECP2	1	105.7×	0.021	PTEN
Regulation of TP53 Degradation	1	97.6×	0.021	CHEK2
Negative regulation of the PI3K/AKT network	1	92.8×	0.021	PTEN
Ovarian tumor domain proteases	1	92.8×	0.021	PTEN
Synthesis of PIPs at the plasma membrane	1	70.5×	0.024	PTEN
Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A	1	68.0×	0.024	CHEK2
Regulation of PTEN stability and activity	1	61.4×	0.024	PTEN
Regulation of PTEN gene transcription	1	59.5×	0.024	PTEN
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	1	48.8×	0.027	CHEK2
TP53 Regulates Metabolic Genes	1	43.3×	0.027	PTEN
Downstream TCR signaling	1	42.8×	0.027	PTEN
G2/M DNA damage checkpoint	1	40.1×	0.027	CHEK2
Regulation of TP53 Activity through Phosphorylation	1	39.2×	0.027	CHEK2
Mitochondrial protein degradation	1	38.1×	0.027	FH
Ub-specific processing proteases	1	17.7×	0.055	PTEN

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
fumarate metabolic process	1	5617.3×	0.007	FH
obsolete regulation of arginine metabolic process	1	2808.7×	0.007	FH
negative regulation of synaptic vesicle clustering	1	2808.7×	0.007	PTEN
negative regulation of keratinocyte migration	1	1872.4×	0.007	PTEN
negative regulation of DNA damage checkpoint	1	1872.4×	0.007	CHEK2
mitotic DNA damage checkpoint signaling	1	1404.3×	0.007	CHEK2
rhythmic synaptic transmission	1	1404.3×	0.007	PTEN
cellular response to bisphenol A	1	1123.5×	0.007	CHEK2
central nervous system myelin maintenance	1	936.2×	0.007	PTEN
arginine metabolic process	1	802.5×	0.007	FH
negative regulation of cell cycle G1/S phase transition	1	802.5×	0.007	PTEN
response to glycoside	1	802.5×	0.007	CHEK2
negative regulation of wound healing, spreading of epidermal cells	1	802.5×	0.007	PTEN
malate metabolic process	1	624.1×	0.007	FH
spindle assembly involved in female meiosis	1	624.1×	0.007	PTEN
central nervous system neuron axonogenesis	1	624.1×	0.007	PTEN
postsynaptic density assembly	1	624.1×	0.007	PTEN
positive regulation of anoikis	1	624.1×	0.007	CHEK2
neuron-neuron synaptic transmission	1	561.7×	0.007	PTEN
negative regulation of peptidyl-serine phosphorylation	1	561.7×	0.007	PTEN
negative regulation of cell size	1	561.7×	0.007	PTEN
presynaptic membrane assembly	1	561.7×	0.007	PTEN
negative regulation of organ growth	1	468.1×	0.007	PTEN
forebrain morphogenesis	1	468.1×	0.007	PTEN
thymocyte apoptotic process	1	468.1×	0.007	CHEK2
urea cycle	1	432.1×	0.007	FH
multicellular organismal response to stress	1	432.1×	0.007	PTEN
negative regulation of axonogenesis	1	432.1×	0.007	PTEN
cellular response to electrical stimulus	1	432.1×	0.007	PTEN
negative regulation of excitatory postsynaptic potential	1	432.1×	0.007	PTEN

Therapeutics

Drugs indicated for this disease

1 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Trabectedin	Approved (phase 4)
Catequentinib	Phase 3 (in late-stage trials)
Dacarbazine	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Ifosfamide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Avelumab, Bevacizumab, Carboplatin, Dinutuximab, Gemcitabine, Ipilimumab, Letrozole, Lurbinectedin, Nivolumab, Olaparib, Pazopanib, Ridaforolimus, Rucaparib, Temozolomide.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CHEK2	NERATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CHEK2	30	4
FH	0	0
PTEN	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NERATINIB	4	CHEK2
BOSUTINIB	4	CHEK2
BRIGATINIB	4	CHEK2
SUNITINIB	4	CHEK2
GEFITINIB	4	CHEK2
FASUDIL	3	CHEK2
CEDIRANIB	3	CHEK2
DOVITINIB	3	CHEK2
LESTAURTINIB	3	CHEK2
RUBOXISTAURIN	3	CHEK2
DORAMAPIMOD	2	CHEK2
FORETINIB	2	CHEK2
SU-014813	2	CHEK2
CENISERTIB	2	CHEK2
ILORASERTIB	2	CHEK2
CEP-11981	2	CHEK2
DEFOSBARASERTIB	2	CHEK2
PREXASERTIB	2	CHEK2
BI-2536	2	CHEK2
UCN-01	2	CHEK2
PF-00562271	1	CHEK2
KW-2449	1	CHEK2
RG-1530	1	CHEK2
MLN-8054	1	CHEK2
PF-03758309	1	CHEK2
SRA-737	1	CHEK2
SNS-314	1	CHEK2
CYC-116	1	CHEK2
GSK-690693	1	CHEK2
AST-487	1	CHEK2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CHEK2	690	Binding:687, Functional:2, ADMET:1
PTEN	8	Binding:8
FH	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
FH	4.2.1.2	fumarate hydratase
PTEN	3.1.3.16, 3.1.3.67	protein-serine/threonine phosphatase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase
CHEK2	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CHEK2	690

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
NERATINIB	4	CHEK2
BOSUTINIB	4	CHEK2
BRIGATINIB	4	CHEK2
SUNITINIB	4	CHEK2
GEFITINIB	4	CHEK2
FASUDIL	3	CHEK2
DOVITINIB	3	CHEK2
LESTAURTINIB	3	CHEK2
RUBOXISTAURIN	3	CHEK2
DORAMAPIMOD	2	CHEK2
FORETINIB	2	CHEK2
SU-014813	2	CHEK2
CENISERTIB	2	CHEK2
ILORASERTIB	2	CHEK2
CEP-11981	2	CHEK2
DEFOSBARASERTIB	2	CHEK2
PREXASERTIB	2	CHEK2
BI-2536	2	CHEK2
UCN-01	2	CHEK2
PF-00562271	1	CHEK2
KW-2449	1	CHEK2
RG-1530	1	CHEK2
MLN-8054	1	CHEK2
PF-03758309	1	CHEK2
SRA-737	1	CHEK2
SNS-314	1	CHEK2
CYC-116	1	CHEK2
GSK-690693	1	CHEK2
AST-487	1	CHEK2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CHEK2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	2	FH, PTEN
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
FH	1	—
PTEN	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 101.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	49
PHASE1	18
Not specified	17
PHASE1/PHASE2	9
PHASE3	6
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02180867	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT03016819	PHASE3	RECRUITING	Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
NCT04031677	PHASE3	RECRUITING	Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT06088290	PHASE3	ACTIVE_NOT_RECRUITING	Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT01343277	PHASE3	COMPLETED	A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
NCT01692678	PHASE3	COMPLETED	A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
NCT03773510	PHASE3	WITHDRAWN	Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
NCT05269355	PHASE2/PHASE3	TERMINATED	A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT02203760	PHASE2	ACTIVE_NOT_RECRUITING	Pazopanib Vs. Pazopanib Plus Gemcitabine
NCT02275286	PHASE1/PHASE2	RECRUITING	Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
NCT02923778	PHASE2	ACTIVE_NOT_RECRUITING	Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
NCT03851614	PHASE2	ACTIVE_NOT_RECRUITING	Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
NCT04200443	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
NCT04535271	PHASE2	RECRUITING	Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
NCT04554914	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04624178	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
NCT05099666	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Lurbinectedin + Doxorubicin In Leiomyosarcoma
NCT05836571	PHASE2	ACTIVE_NOT_RECRUITING	Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT06277154	PHASE2	RECRUITING	MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
NCT06498648	PHASE1/PHASE2	RECRUITING	Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
NCT06528769	PHASE2	RECRUITING	Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
NCT06571734	PHASE2	RECRUITING	XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT06849986	PHASE2	RECRUITING	IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
NCT06975293	PHASE1/PHASE2	RECRUITING	STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT07169344	PHASE2	RECRUITING	Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
NCT07173972	PHASE2	RECRUITING	Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
NCT07516925	PHASE2	RECRUITING	A Study of Ivonescimab in People With Leiomyosarcoma
NCT00060944	PHASE2	COMPLETED	A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
NCT00093080	PHASE2	COMPLETED	Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
NCT00282087	PHASE2	COMPLETED	Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
NCT00356031	PHASE2	COMPLETED	Bevacizumab and Radiation Therapy for Sarcomas
NCT00400569	PHASE2	COMPLETED	Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
NCT00414076	PHASE2	TERMINATED	Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
NCT00503295	PHASE2	COMPLETED	Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
NCT00668148	PHASE2	COMPLETED	A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
NCT00815945	PHASE2	COMPLETED	Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
NCT00837148	PHASE2	COMPLETED	Sorafenib and Dacarbazine in Soft Tissue Sarcoma
NCT00856050	PHASE2	COMPLETED	Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
NCT00887809	PHASE2	COMPLETED	Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRABECTEDIN	4	11
PAZOPANIB	4	6
DACARBAZINE	4	5
DEXRAZOXANE	4	3
AVELUMAB	4	2
CABOZANTINIB	4	2
CEMIPLIMAB	4	2
ERIBULIN	4	2
LURBINECTEDIN	4	2
TABELECLEUCEL	4	2
DEOXYCHOLIC ACID	4	1
DIGOXIN	4	1
DINUTUXIMAB BETA	4	1
FUTIBATINIB	4	1
IFOSFAMIDE	4	1
NIRAPARIB TOSYLATE MONOHYDRATE	4	1
OLARATUMAB	4	1
RUCAPARIB	4	1
SUNITINIB MALATE	4	1
TALIMOGENE LAHERPAREPVEC	4	1
ZANZALINTINIB	3	2
ALISERTIB	3	1
CATEQUENTINIB	3	1
CEDIRANIB	3	1
ITACITINIB	3	1
RIDAFOROLIMUS	3	1
VIMSELTINIB	3	1
ELRAGLUSIB	2	2
UNESBULIN	2	2
BERZOSERTIB	2	1